Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is a leading player in the Chinese pharmaceutical industry, specializing in traditional Chinese medicine and modern pharmaceuticals. The company benefits from a strong distribution network across China and a diverse product portfolio that includes over 200 proprietary medicines, which provides a competitive edge in the rapidly growing healthcare market.
The company generates revenue primarily through the sale of traditional Chinese medicine and modern pharmaceuticals, leveraging its extensive distribution network and brand recognition. Its competitive advantages include a strong R&D pipeline, regulatory compliance expertise, and established relationships with healthcare providers.
Regulatory approvals for new drug formulations
Changes in healthcare policies affecting traditional medicine
Market expansion efforts in Southeast Asia
Fluctuations in raw material costs for pharmaceuticals
Regulatory changes impacting the approval process for traditional medicines
Technological disruption in drug manufacturing processes
Increased competition from domestic and international pharmaceutical companies
Potential market entry of generic versions of proprietary drugs
Low liquidity risk due to strong cash flow generation
Potential exposure to foreign exchange fluctuations due to international sales
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but consumer spending on healthcare can be affected by GDP growth.
Low - The company has minimal debt, so rising interest rates do not significantly impact financing costs. However, higher rates could affect consumer spending on healthcare.
minimal - The company’s low debt levels reduce its exposure to credit conditions.
value - The company's strong margins and low debt levels appeal to value investors looking for stability.
low - The stock has shown relatively stable performance with a 1-year return of 27.4%.